| Identification | Back Directory | [Name]
evobrutinib | [CAS]
1415823-73-2 | [Synonyms]
M2951
140920
evobrutinib
MSC2364447C
M2951; MSC2364447C
Evobrutinib (M2951)
M-2951 (Evobrutinib)
1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one
1-[4-({[6-Amino-5-(4-phenoxyphenyl)-4-pyrimidinyl]amino}methyl)-1-piperidinyl]-2-propen-1-one
2-Propen-1-one, 1-[4-[[[6-amino-5-(4-phenoxyphenyl)-4-pyrimidinyl]amino]methyl]-1-piperidinyl]- | [Molecular Formula]
C25H27N5O2 | [MDL Number]
MFCD30502975 | [MOL File]
1415823-73-2.mol | [Molecular Weight]
429.51 |
| Chemical Properties | Back Directory | [Melting point ]
173 - 174oC | [Boiling point ]
683.4±55.0 °C(Predicted) | [density ]
1.227±0.06 g/cm3(Predicted) | [storage temp. ]
Hygroscopic, -20°C Freezer, Under inert atmosphere | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
5.29±0.10(Predicted) | [color ]
White to Off-White | [Stability:]
Hygroscopic |
| Hazard Information | Back Directory | [Uses]
Evobrutinib is a highly selective inhibitor of the Bruton’s tyrosine kinase (BTK), which is important in the -development and functioning of various immune cells including B -lymphocytes and macrophages. Preclinical research suggests it may be therapeutically useful in certain autoimmune diseases. | [in vivo]
Evobrutinib (0.3, 1, 3, 10, or 30 mg/kg, oral gavage, once daily) demonstrates efficacy in a rat model of rheumatoid arthritis[1]. | Animal Model: | Female Lewis rats with semi-established type II collagen arthritis[1]. | | Dosage: | 0.3, 1, 3, 10, or 30 mg/kg. | | Administration: | Oral gavage once daily for 11 days (days 6-16). | | Result: | Reduced ankle histopathology scores in a dose-dependent manner, compared to vehicle. |
| [storage]
Store at -20°C |
|
|